argenx publishes positive results from efgartigimod Phase 2 ITP trial
Category: #health  By Mateen Dalal  Date: 2019-12-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

argenx publishes positive results from efgartigimod Phase 2 ITP trial

argenx, a renowned Netherlands based biotechnology firm, reportedly announced the publication of outcomes from the assessment of its FcRn antagonist, efgartigimod, in a Phase 2 ITP clinical trial, in the American Journal of Hematology.

Wim Parys, M.D., chief medical officer, argenx, reportedly stated that efgartigimod showcased a favorable tolerability and the capability to drive encouraging response rates across a refractory demographic after a limited exposure. Parys further added that the company is thrilled to announce the publication of efgartigimod Phase 2 ITP trial results as a new treatment modality in ITP. The company is now looking forward towards advancing efgartigimod into a global Phase 3 ITP program before 2019 ends, where the company would get the opportunity to dose participants in a long-term setting.

The global Phase 3 program in ITP remains on track to start this month and would assess the intravenous (IV) formulation inside the first clinical trial, ADVANCE, along with an IV induction that would be followed by a SC (subcutaneous) maintenance injection in the second trial, ADVANCE SC.

Additionally, efgartigimod is also presently being evaluated for the treatment of serious autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG) and pemphigus vulgaris (PV).

The ADAPT Phase 3 trial of IV efgartigimod in gMG is in progress with data expected in the last two quarters of 2020. A Phase 2 PoC (proof-of-concept) is also in progress in PV and data is expected in the first two quarters of 2020. Meanwhile, a Phase 2 PoC (proof-of-concept) trial of efgartigimod SC in CIDP is expected to start before the end of 2019.

About argenx:

argenx, is a renowned biopharmaceutical firm. It develops and creates a pipeline of differentiated anti-body therapeutics using its Simple Antibody platform, which is based on the powerful llama immune system. The firm develops a deep pipeline of anti-body therapeutics that focuses on cancer and auto-immune diseases.

It creates antibodies that have the best in class therapeutic potential. It includes: ARGX-111, an antagonist of c-Met; a receptor involved in cell proliferation, metastasis and angiogenesis in multiple solid tumors; ARGX-112, an antigen targeting atopic dermatitis, among others.
 

Source credit: https://www.argenx.com/en-GB/news-internal/argenx-announces-publication-of-efgartigimod-phase-2-primary-immune-thrombocytopenia-trial-results-in-american-journal-of-hematology/30242/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Meter nabs $38Mn to scale business & support faster enterprise internet
Meter nabs $38Mn to scale business & support faster enterprise internet
By Mateen Dalal

Meter, Inc., an internet & Wi-Fi infrastructure provider for businesses, has recently announced that it has successfully raised $38 million in a Series B funding round that was headed by Lachy Groom and Sequoia Capital. Industry leaders like D...

MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
By Mateen Dalal

The BNPL (book now pay later) payment has been introduced on MakeMyTrip on bookings for flights, travel, or hotels as well as on the Goibibo app MakeMyTrip, the online travel company, has recently said that it has collaborated with 15 banks, finte...

BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
By Mateen Dalal

BlackBerry Limited, a Canada-based software company focused on cybersecurity, has recently entered into a partnership with Midis Group, a leading technology company offering advanced hardware and software solutions, to expand its market footprint acr...